These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 28129118)

  • 1. CRISPR/Cas9-Induced (CTG⋅CAG)
    van Agtmaal EL; André LM; Willemse M; Cumming SA; van Kessel IDG; van den Broek WJAA; Gourdon G; Furling D; Mouly V; Monckton DG; Wansink DG; Wieringa B
    Mol Ther; 2017 Jan; 25(1):24-43. PubMed ID: 28129118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice.
    Lo Scrudato M; Poulard K; Sourd C; Tomé S; Klein AF; Corre G; Huguet A; Furling D; Gourdon G; Buj-Bello A
    Mol Ther; 2019 Aug; 27(8):1372-1388. PubMed ID: 31253581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells.
    Dastidar S; Ardui S; Singh K; Majumdar D; Nair N; Fu Y; Reyon D; Samara E; Gerli MFM; Klein AF; De Schrijver W; Tipanee J; Seneca S; Tulalamba W; Wang H; Chai YC; In't Veld P; Furling D; Tedesco FS; Vermeesch JR; Joung JK; Chuah MK; VandenDriessche T
    Nucleic Acids Res; 2018 Sep; 46(16):8275-8298. PubMed ID: 29947794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.
    Wang Y; Hao L; Wang H; Santostefano K; Thapa A; Cleary J; Li H; Guo X; Terada N; Ashizawa T; Xia G
    Mol Ther; 2018 Nov; 26(11):2617-2630. PubMed ID: 30274788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities.
    Raaijmakers RHL; Ripken L; Ausems CRM; Wansink DG
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery in the Myogenic Program of Congenital Myotonic Dystrophy Myoblasts after Excision of the Expanded (CTG)
    André LM; van Cruchten RTP; Willemse M; Bezstarosti K; Demmers JAA; van Agtmaal EL; Wansink DG; Wieringa B
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
    André LM; van Cruchten RTP; Willemse M; Wansink DG
    PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes.
    Dastidar S; Majumdar D; Tipanee J; Singh K; Klein AF; Furling D; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Jan; 30(1):75-91. PubMed ID: 34371182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat.
    Gudde AEEG; van Heeringen SJ; de Oude AI; van Kessel IDG; Estabrook J; Wang ET; Wieringa B; Wansink DG
    RNA Biol; 2017 Oct; 14(10):1374-1388. PubMed ID: 28102759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.
    Gudde AE; González-Barriga A; van den Broek WJ; Wieringa B; Wansink DG
    Hum Mol Genet; 2016 Apr; 25(8):1648-62. PubMed ID: 26908607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.
    Izzo M; Battistini J; Provenzano C; Martelli F; Cardinali B; Falcone G
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trinucleotide-repeat expanded and normal DMPK transcripts contain unusually long poly(A) tails despite differential nuclear residence.
    Gudde AEEG; van Kessel IDG; André LM; Wieringa B; Wansink DG
    Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):740-749. PubMed ID: 28435090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MSH2 knock-down shows CTG repeat stability and concomitant upstream demethylation at the DMPK locus in myotonic dystrophy type 1 human embryonic stem cells.
    Franck S; Barbé L; Ardui S; De Vlaeminck Y; Allemeersch J; Dziedzicka D; Spits C; Vanroye F; Hilven P; Duqué G; Vermeesch JR; Gheldof A; Sermon K
    Hum Mol Genet; 2021 Jan; 29(21):3566-3577. PubMed ID: 33242073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
    Wojciechowska M; Sobczak K; Kozlowski P; Sedehizadeh S; Wojtkowiak-Szlachcic A; Czubak K; Markus R; Lusakowska A; Kaminska A; Brook JD
    Sci Rep; 2018 Apr; 8(1):5885. PubMed ID: 29651162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts.
    Langlois MA; Lee NS; Rossi JJ; Puymirat J
    Mol Ther; 2003 May; 7(5 Pt 1):670-80. PubMed ID: 12718910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded CUG repeats in
    van Cruchten RTP; Wieringa B; Wansink DG
    RNA; 2019 Apr; 25(4):481-495. PubMed ID: 30700578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resection and repair of a Cas9 double-strand break at CTG trinucleotide repeats induces local and extensive chromosomal deletions.
    Mosbach V; Viterbo D; Descorps-Declère S; Poggi L; Vaysse-Zinkhöfer W; Richard GF
    PLoS Genet; 2020 Jul; 16(7):e1008924. PubMed ID: 32673314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.